8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 5, 2010

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50761	11-3146460
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

603 Queensbury Avenue, Queensbury, New York      12804

(Address of Principal Executive Offices)                 (Zip Code)

(518) 798-1215

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 2.02 – Results of Operations and Financial Condition.

On September 7, 2010, AngioDynamics, Inc. (the “Company”) issued a press release announcing preliminary results for the fiscal first quarter ended August 30, 2010.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This document and its attachments include "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "estimate," "seek," "continue," "pursue," or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular, they include statements relating to, among other things, future actions, strategies, future performance and future financial results of the Company.  These forward-looking statements are based on current expectations and projections about future events.

Investors are cautioned that forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties that cannot be predicted or quantified and, consequently, the actual performance or results of the Company may differ materially from those expressed or implied by such forward-looking statements.  Such risks and uncertainties include, but are not limited to, the factors described from time to time in the Company's reports filed with the SEC, including the Company's Form 10-K for the fiscal year ended May 31, 2010, financial community and rating agency perceptions of the Company; the effects of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; domestic and foreign health care reforms and governmental laws and regulations; third-party relations and approvals, technological advances and patents attained by competitors; and challenges inherent in new product development, including obtaining regulatory approvals.  In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the outcome of pending litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, and the effects on pricing from group purchasing organizations and competition and the ability of the Company to integrate purchased businesses, may affect the actual results achieved by the Company.

Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

Item 9.01 – Financial Statements and Exhibits.

(d)               Exhibits.

Exhibit No.	Description
99.1	Press Release dated September 7, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANGIODYNAMICS, INC. (Registrant)
Date: September 7, 2010	By:	/s/  D. Joseph Gersuk
		D. Joseph Gersuk
		Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated September 7, 2010.

EX-99.1

EXHIBIT 99.1

Company Contact:	Investor Relations Contacts:	Media Contact:
AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com	EVC Group, Inc. Doug Sherk / Gregory Gin (415) 896-6820 dsherk@evcgroup.com ggin@evcgroup.com	EVC Group, Inc. Chris Gale (646) 201-5431 cgale@evcgroup.com

ANGIODYNAMICS REPORTS PRELIMINARY FISCAL 2011

FIRST QUARTER RESULTS

ALBANY, N.Y. September 7, 2010—AngioDynamics (NASDAQ: ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported preliminary unaudited results for its fiscal 2011 first quarter ended August 31, 2010.

AngioDynamics expects first quarter net sales to be approximately $51.5 million, or approximately 3% higher than fiscal 2010 first quarter net sales of $50.1 million.  Oncology/Surgery sales grew approximately 22% to $15.6 million from the first quarter of fiscal 2010 and included $1.1 million of NanoKnife® System sales.  Peripheral Vascular sales decreased approximately 1% to $20.7 million and Access sales decreased approximately 6% to $15.2 million compared with the same period of the prior year.  Earnings per share for the quarter are currently expected to be in the range of $0.07 - $0.08 compared with $0.09 for the fiscal first quarter of 2010.

“Our first quarter sales of Access and Peripheral Vascular products were affected by a procedure volume slowdown in some of our U.S. markets, the challenging pricing environment that has persisted for the past year, and the transition to a unified vascular sales force that we implemented effective June 1, 2010,” said Jan Keltjens, President and Chief Executive Officer.  “We remain focused on building the organizational capabilities required to address the significant opportunities ahead of us. The organizational changes we have implemented combined with the ongoing introduction of innovative products, and continued progress with our NanoKnife program, will enable us to maximize our short and longer term growth opportunities.”

Final results for the fiscal first quarter are expected to be released on October 7, 2010.  With this release, the Company is expected to update its outlook for the fiscal year.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. AngioDynamics’ diverse product lines include market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties.  Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations.  Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2010.  AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

GRAPHIC 3 an20554981-ex99_10.jpg begin 644 an20554981-ex99_10.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,`!`,#!`,# M!`0#!`4$!`4&"@<&!@8�D*"`H/#1`0#PT/#A$3&!01$A<2#@\5'!47&1D; M&QL0%!T?'1H?&!H;&O_;`$,!!`4%!@4&#`<'#!H1#Q$:&AH:&AH:&AH:&AH: M&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&O_``!$(`$H! M7@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/OZBBB@!#S1BD.BM.W MOK>Y`-O,D@/]ULT:`ZIQP*^>]*^&4GC+X::_J^ MJQ;]4U=FN8F8?,H'W143O:R/H\E]A1K*OB%>.WW_`.1[3\*?%T7C+P7IFHPM MN>C`,E!;/5>C)O,IV:^6_BMXO\6?"GQ7IT\&JS:CI4S;I('7 M)"CK7OO@SQA8>--!M]2TR8.DJ#<`>5/H:%+6QCB,OJT:$:][QEU1TI?'I2[S M7C?C2+6[;Q]X?LK#6[F"SU%W\V,8XP">/RIOQ#^)UQX:O+'PMX:/V_Q!=X4, MW.P?WC3;L3'!3J%/'.A65SJ+ZAH5U*4WL/F#8X!IW$L-&3:C--H]O+XI/,KP3]H M;6->\'Z)#J^@:Q-;/),L;1\;>:ZSP[KS>%_A[!XB\3:G+=L]HLSF0CJ1G`I7 MLS1X"?L(UHN_,[)=3U#S.O84T2AC\I!'M7AG@R_\2?%L3:O/?S:/H9Y!IIZ7)>"M4]C*24NWZ'I M7B[PWI^O:3="_@60B)L'N.*^)?@[X9M?$_Q6O=&U:2:6RA,I5/,/9N*^P_"' MCNR\?^#WU.P(&Z%A(F>5;'(KY9_9]'_%]-3_`.VW_H593U:/ILI56AA,53EH MXH^C[WX#>$[FV,<5O+;MCAXY2"*\%\?:#XS^!U]'JV@:I]%NS3,#X/_`!2M M/B5X=2Z0A+Z'Y+B//0^M>D>9CC-?`G[.UY=V/C^[T.UNY+5;M'3$_BI::%XMUZX71[F7$4P`&X'H,TE/W3T\QR-4\9.G2E96YDO(^M2QQ M2"2LF]E1-'E)[W4=0U#7[I='$[)9K@`NH[U MHV?-4L-[2G*;DDH]SW7S,GCFE+\<5\O?%KQ;XM^$_B;2[JUU:;4M+G):2!QD MA0>:]Y\$>,K'QQH5OJ6FRAUD4%E!Y4^AI7Z&]?+ZM&C&NM82ZG4"3-+N]*\9 M\>0ZY9>-/#]KIVMW,%KJ,K"6,8X`YXKUFTA:RM%2:5IBB\NW4TSDJ4N2$9)W MN7=W/44N37SBGQKF/QI_L=W*Z.X\A&/W3(#7T4AW(I!R"*+FN)PE7"*+J+XE M<5(-6?@#\2+CQSX;>+5Y-^K M6C[)\]3[XIZCI6JW%ON^(-6GNI7=E M$9P%`%.^HHX-RPSQ'-HG:Q[<7QUIOFY.,BO#_&'Q0U/6/&*>#?`FW[8/^/JZ M/(B'^-=/;_#C44MQ)/XEU%[[&2^\8W?2FF3/".E%.J^6_0]*#\TAEV]3BO$- M$\0^*/#WBW6;;Q7OO6?X#EUKXO17FMW.O7&GV@G:.WMK M9@-H'FXXKQ6V3Q?X:^(VBZ M5?ZI)J&B3ARKN/FR!T)K1^(#7;:DZP[FEW#RU;IMQS3)^J+GC'FT:N>N07:7 M"[H75T/0@YJQFN%\!R%XY!&6:`*G4<;\,/$'BRZE1Y&E\BU4GE4% M?001<=!4KN>]B:L<+&&&E3^'5^K/SW\1W6I^!OBM;>(9=,FT>.XN!((G]"?F MK[UT'58=;TBSO[5@T<\2NN/<5X;^U9X:L]2\&+J!:-+NR?U4_V6OB3 M!JOAPZ%J-RJWEG_J@[8+)[5G%\LK'L9E'^T\LIXN,=8:/T.R^(&CVNN_$70; M#48EE@FMI58,/:O)+:34_P!G;QX;>WEFO)/AA/_`,)%^T%KMSJ/SO;EA$&YVX-4/AY9 M>(/#'Q:T7PGKY>2UM))6M9&[J5-7_%FD7OPB^,47BA(7;1K^3]\ZCA<]S2HTZ'/0C*[E#W7WU/K20E(W*+N91D"O%_$/QKBTSQC:>&]1\/32:A(X, M!W@C/8YKU?1]?T_6K&*\L;J*:&50P*L*^9_B-)'<_M%^&?LQ$@4+N*\X/-6W M:Q\[EF%A6JSA55K1;^:.G_:AFDG^'ED\T7D2-#X,>%; M6(L(YXHA)CTVBNL_:MFC7P-9H77?]I3Y<\U+XP\%-X\^"6EP:=B6[@LXY(P. M22%'%0]V>U@JD*6'PTIZ)29Z-\([6.U^'VA)`H"_95)QZXKH_$UJEYH5_!,H M,;P.&S]*\O\`@#XPAOO"<&C:@PMM3TT>3)#(<-QWYKJ/BCXUL_#7A>^/G*]Y M-$T<$2G+,Q&!@5=]#P:]&I]?<4KOF_IG@W[,%[,A\8:>"QMHG*VMWJ2O,RN<%5Y(KQ;X#ZO96?QIU"ZN MKB."!_-VN[8!^:L7NC[12C76,E2VY4C[O)Q6!XRU*'3O#&J7%RP5$MWR3]*= M>>,-#M+Q*3#"9)&/ID\5]/?'+X;)XX\,226:A M-5LP9;>0?>R.<9JG\!/A*OPYT(RWJAM4N\-*W]T>E>N7CI';R&0C&T]:48Z' MJYMFGMLRC5H;0LEYV/EKP#X[UKXAZ3:^"9$DAO;5_+OYCVC7^IKZ5MN#VS7U;D$<54+VU.+.DH5^2"LFD_F MSR#XBZ/:ZW\0/#5A?1++!/;SHP89&#BO(XWU3]G7QT4?S)_">H2<=Q'DU[)X MONX$^*GA-6E0$13<;OI76>.?!>G>.M`N--U"-7$BGRW[J>Q%#74TH8SV$(4J MNM.2U7SW.)\4ZO;:WXM\"WMC*LL$LCLK`]BM=;\2O$H\->%;J=&"W$P$,`)Z MNW`KYF\#6&O^$/BEI'A77V9[*QEDDM)&Z%#[UZ]XDCL_B9\08-`EF#Z;I<9F MG5'QND/0?A1\$KW\KGG'Q5\"PZ/X"T?6]-FC;5]/D$\S*PW,2 M*?`J7^G*'O].431,O7@9H=KW)RZJH0C1J?#4NG^AT7Q3UI[FRL=!TILWFK MN$^4_=C[G\J\3T/2HM&_:2LK&!0J06FT#_@(KM/@)_:/C(1>)O$2$?9(!:VV M[VX+5R\EU"/VIPPD4*(2N<]]HH;N=6%A]7E6PZUM%W]3W'XQG'PVU_C_`)=' M_E7`?L\7#VWP:::/[T?FE:[KXS7$:_#?7M[J-UJP&3UXKB_V9S!>_"F.U+KE MGD5AGUHENC@H665RM?(_@UY M/@E\7-3L];#0Z1JK$Q3D?)DGCFOJNWUBRNK=9X;N%XV&0P<8HCL+/(^TQ"JT M]8M*WW$.JZ!9ZI%,)XE,DL31%AUP17R=J/AWQU\`]XKZ/U7QIYB:B-''G1VD#L\X^Z&`Z"H?`GC/3/'7AJ":6:&:4J4GB2<5]9VX<0Q[^7VC/UHB MV]RYM#%5X0Y(S:78X2;X4>'KG48=0G@E>[A'R2&0Y7Z M5V=O;+;01PQY*J,#)S5G%%-:&$ZDZBM)W,&]\+Z;?:Q9ZK/;*;ZT)\F7'(R, M&K6JZ+8ZW:O:ZI;1W,#C!5US6I@44#]I.Z=]MCS:+X-Z%:.W]FR7EA$W6."< MJOY5I:%\,/#V@7PO[6S\V^'_`"\3'>_YFNWQ1@4/4T>)K2WDMFNL'(5F.T'Z5K>'/"6G>%K46NE1LD`&T(6)`%=#@48%%M276J2AR-^[ MV.(UGX8:#K%\;[[.UI>'K-;ML8_7%,T[X5Z#9WJ7ES%)?W$9RCW+E]OTS7=T M46&J]5;2.:\0^"M+\31"/4XW:,#;L5RHQ^%<9I\#?!X8>9IWF*/X7B>#-"\.H!H^FV]K[H@S^= M=#BC%%D3/%5ZBM*;L,"@#%4-5TNWU>U:VN]WE-UVM@FM*DP*9@FT[GGFE?!K MPMH>H-?Z79&WNF.2ZNN^6(+'M'3&*FQ126AJQZ MG=0R/>QG*2;SE?I776ULMG;I#'DJ@P,G)JUBC%-!*I.:2;V.JOJ6G6\D5X[;GD#G+?6NYP/2EQ1H4J]6,;* M3*US;I<6[PR9VN,'!KSQ?@CX274SJ:V!%\7WF;>=V?K7I>!Z4N*`IUZM*_([ M7.*U_P"&VA^)$A35H7G2(@JI%6U7^U39-]OSGSMYW9^M M>CXHQ2:N7&O5@VXR>IR>N^`])\1V266JI)/;JNW87."/>H/"WPWT+P:1_8-N MULF<[`QQGZ5V>!1@4]+C]O5Y'#F=GT.=\3>#M&\66OV?7;**Z3L67D?0UR5G M\%/#]@P%O)?"$'_5?:&V?3%>GX%&*`CB*L(\JEH8D/AO3K;2WTZWMTBM70HR MJ.H/6N4?X.^&D4"P@DT]^[VSE"?K7HV*,"@F-:K!.TMSBO#?PVT/PS>&]M+= MIKQAS/.V]_S-=D`.W2GX%'2@F3N%%%%!`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 =44`%%%%`!1110`4444`%%%%`!1110`4444`?_]D_ ` end -----END PRIVACY-ENHANCED MESSAGE-----